عرض بسيط للتسجيلة

المؤلفAl-Ziftawi, Nour Hisham
المؤلفAlam, Mohammed Fasihul
المؤلفElazzazy, Shereen
المؤلفShafie, Asrul Akmal
المؤلفHamad, Anas
المؤلفMohamed Ibrahim, Mohamed Izham
تاريخ الإتاحة2023-01-16T07:45:45Z
تاريخ النشر2022-12-28
اسم المنشورInternational journal of environmental research and public health
المعرّفhttp://dx.doi.org/10.3390/ijerph20010512
الاقتباسAl-Ziftawi, N.H.; Alam, M.F.; Elazzazy, S.; Shafie, A.A.; Hamad, A.; Mohamed Ibrahim, M.I. Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation. Int. J. Environ. Res. Public Health 2023, 20, 512. https://doi.org/10.3390/ijerph20010512
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85145972957&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/38437
الملخصPalbociclib and ribociclib are indicated in the first-line treatment of hormonal-receptor-positive HER-2 negative (HR+/HER-2 negative) advanced breast cancer. Despite their clinical benefit, they can increase healthcare expenditure. Yet, there are no comparative pharmacoeconomic evaluations for them in developing countries, the Middle East, or Gulf countries. This study compared the cost-effectiveness of palbociclib and ribociclib in Qatar. A 10-year within-cycle-corrected Markov's model was developed using TreeAge Pro® software. The model consisted of three main health states: progression-free (PFS), progressed-disease (PD), and death. Costs were obtained from the actual hospital settings, transition probabilities were calculated from individual-patient data, and utilities were summarized from the published literature. The incremental cost-effectiveness ratio (ICER) and the incremental cost-utility ratio (ICUR) were calculated and compared to three gross-domestic-products per capita. Deterministic and probabilistic sensitivity analyses were performed. Ribociclib dominated palbociclib in terms of costs, life-years gained, and quality-adjusted life-years gained. The conclusions remained robust in the different cases of the deterministic sensitivity analyses. Taking all combined uncertainties into account, the confidence in the base-case conclusion was approximately 60%. Therefore, in HR+/HER-2 negative stage IV breast cancer patients, the use of ribociclib is considered cost-saving compared to palbociclib.
راعي المشروعThis study was funded by Qatar University, by financial grant #No. QUST-1-CPH-2019-12.
اللغةen
الناشرMDPI
الموضوعadvanced breast cancer
cost-effectiveness
cost-saving
cost-utility
cyclin-dependent-kinase 4/6 inhibitors
العنوانCost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation
النوعArticle
رقم العدد1
رقم المجلد20
ESSN1660-4601
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة